Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaMarco L. Davila, Renier J. Brentjens, Sergio Giralt et al.|Science Translational Medicine|2014Cited by 2.5k
Gene therapy comes of ageCynthia E. Dunbar, Michel Sadelain, Katherine A. High et al.|Science|2018Cited by 1.4k
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escapeMohamad Hamieh, Michel Sadelain, Anton Dobrin et al.|Nature|2019Cited by 659
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent PembrolizumabPrasad S. Adusumilli, Michel Sadelain|Cancer Discovery|2021Cited by 551
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapyMelody Smith, Marco Ruella, Anqi Dai et al.|Nature Medicine|2022Cited by 308